ZGNX - Zogenix: Market Reaction To Fintepla's Approval Offers A Gift To Investors
With the highly volatile markets fueled by rising algorithmic and day trading, it is increasingly common to see wide swings in stocks, particularly in the biotech sector. Therefore, one must be prepared to have the courage of one's convictions and accumulate fundamentally strong stocks on dips. Many times, that is the way real money can be made in the sector. This was the case on Friday with Zogenix (ZGNX) shares, which traded down significantly on FDA approval of the company's lead product Fintepla®, a treatment for the rare and severe epilepsy condition Dravet Syndrome, "DS".